Sunvozertinib (DZD9008) is an oral, potent, and selective inhibitor of ErbBs (EGFR or Her2), particularly mutant forms of ErbBs. It also inhibits EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, Her2 exon 20 YVMA, and EGFR WT A431, with IC50 values of 20.4 nM, 20.4 nM, 1.1 nM, […]

6K465 is a pyrimidine-based inhibitor of Aurora A, that reduces levels of c-MYC and N-MYC oncoproteins. It demonstrates compelling antitumor efficacy.

6K465 is a pyrimidine-based inhibitor of Aurora A, that reduces levels of c-MYC and N-MYC oncoproteins. It demonstrates compelling antitumor efficacy.

6K465 is a pyrimidine-based inhibitor of Aurora A, that reduces levels of c-MYC and N-MYC oncoproteins. It demonstrates compelling antitumor efficacy.

SKLB-D18 is a first-in-class, potent, and selective inhibitor of ERK1/2 and ERK5 with an IC50’s of 38.69 nM, 40.12 nM, and 59.72 nM, respectively, that also acts as an agonist of autophagy. It modulates mTOR/p70S6K and NCOA4-mediated ferroptosis, showing strong anti-tumor activity and offering a promising monotherapy strategy to overcome resistance in ERK1/2-targeted therapy for […]

6K465 is a pyrimidine-based inhibitor of Aurora A, that reduces levels of c-MYC and N-MYC oncoproteins. It demonstrates compelling antitumor efficacy.

SKLB-D18 is a first-in-class, potent, and selective inhibitor of ERK1/2 and ERK5 with an IC50’s of 38.69 nM, 40.12 nM, and 59.72 nM, respectively, that also acts as an agonist of autophagy. It modulates mTOR/p70S6K and NCOA4-mediated ferroptosis, showing strong anti-tumor activity and offering a promising monotherapy strategy to overcome resistance in ERK1/2-targeted therapy for […]

SKLB-D18 is a first-in-class, potent, and selective inhibitor of ERK1/2 and ERK5 with an IC50’s of 38.69 nM, 40.12 nM, and 59.72 nM, respectively, that also acts as an agonist of autophagy. It modulates mTOR/p70S6K and NCOA4-mediated ferroptosis, showing strong anti-tumor activity and offering a promising monotherapy strategy to overcome resistance in ERK1/2-targeted therapy for […]

SKLB-D18 is a first-in-class, potent, and selective inhibitor of ERK1/2 and ERK5 with an IC50’s of 38.69 nM, 40.12 nM, and 59.72 nM, respectively, that also acts as an agonist of autophagy. It modulates mTOR/p70S6K and NCOA4-mediated ferroptosis, showing strong anti-tumor activity and offering a promising monotherapy strategy to overcome resistance in ERK1/2-targeted therapy for […]

MTT5 is an agonist of TLR7 that activates dendritic cells and CD8⁺ T cells, enhancing immune responses in the tumor microenvironment. When linked to an ADC, it enhances antitumor efficacy through combined immune stimulation and cytotoxicity.